82 related articles for article (PubMed ID: 11138464)
1. Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump.
Fournet A; Gilard V; Malet-Martino M; Martino R; Canal P; De Forni M
Cancer Chemother Pharmacol; 2000; 46(6):501-6. PubMed ID: 11138464
[TBL] [Abstract][Full Text] [Related]
2. Hydrolytic pathway of 5-fluorouracil in aqueous solutions for clinical use.
Legay R; Massou S; Azéma J; Martino R; Malet-Martino M
J Pharm Biomed Anal; 2014 Sep; 98():446-62. PubMed ID: 25038499
[TBL] [Abstract][Full Text] [Related]
3. Long-term physico-chemical stability of 5-fluorouracile at standardised rounded doses (SRD) in MyFuser® portable infusion pump.
Closset M; Onorati S; Colsoul ML; Goderniaux N; Bihin B; Jamart J; Soumoy L; Hecq JD; Odou P; Galanti L
J Chemother; 2021 Nov; 33(7):486-491. PubMed ID: 33835887
[TBL] [Abstract][Full Text] [Related]
4. [Stability of 5-fluorouracil solutions according to different parameters].
Barberi-Heyob M; Watelet M; Merlin JL; Bleger C; Schroeder B
Bull Cancer; 1995 Dec; 82(12):1025-31. PubMed ID: 8745668
[TBL] [Abstract][Full Text] [Related]
5. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE
NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037
[TBL] [Abstract][Full Text] [Related]
6. [Stability of 5-fluorouracil-folinic acid mixture: influence of concentrations, container and form of folinic acid].
Lokiec F; Amirault P; Bonnans H; Gauzan MF; Sauvage N; Santoni J
Bull Cancer; 1999 Nov; 86(11):946-54. PubMed ID: 10586111
[TBL] [Abstract][Full Text] [Related]
7. Compatibility study of 5-fluorouracil with PVC bags after repackaging into two types of infusion admixtures.
Benaji B; Faouzi MA; Dine T; Goudaliez F; Luyckx M; Brunet C; Kablan J; Gressier B; Cazin M; Cazin JC
Therapie; 1999; 54(5):659-63. PubMed ID: 10667105
[TBL] [Abstract][Full Text] [Related]
8. Stability of fluorouracil administered through four portable infusion pumps.
Stiles ML; Allen LV; Tu YH
Am J Hosp Pharm; 1989 Oct; 46(10):2036-40. PubMed ID: 2816958
[TBL] [Abstract][Full Text] [Related]
9. Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs.
Rochard EB; Barthès DM; Courtois PY
Am J Hosp Pharm; 1992 Mar; 49(3):619-23. PubMed ID: 1598939
[TBL] [Abstract][Full Text] [Related]
10. Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs.
Martel P; Petit I; Pinguet F; Poujol S; Astre C; Fabbro M
J Pharm Biomed Anal; 1996 Feb; 14(4):395-9. PubMed ID: 8729637
[TBL] [Abstract][Full Text] [Related]
11. [Performance of a portable continuous infusion pump (SUREFUSER A) in continuous infusion of 5-FU].
Kimata T; Sakamoto E; Kawachi A; Takahashi Y; Kuroki A; Nakamura M; Kawade Y; Tokui K; Suzuki T; Oyama T; Uchida T; Yamada T; Kondoh M; Ogura M
Gan To Kagaku Ryoho; 2010 Aug; 37(8):1513-8. PubMed ID: 20716877
[TBL] [Abstract][Full Text] [Related]
12. Superiority of hepatic arterial infusion in preventing catabolism of 5-FU compared with portal vein infusion revealed by an in vivo 19F NMR study.
Okuno K; Hirai N; Lee YS; Tarabar D; Ueno H; Yasutomi M
Cancer Chemother Pharmacol; 1998; 42(4):341-4. PubMed ID: 9744781
[TBL] [Abstract][Full Text] [Related]
13. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
Hull WE; Port RE; Herrmann R; Britsch B; Kunz W
Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
15. Fluorine nuclear magnetic resonance spectroscopy of human biofluids in the field of metabolic studies of anticancer and antifungal fluoropyrimidine drugs.
Malet-Martino M; Gilard V; Desmoulin F; Martino R
Clin Chim Acta; 2006 Apr; 366(1-2):61-73. PubMed ID: 16337167
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment energy status of primary rat tumours as the best predictor of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo.
Lemaire LP; McSheehy PM; Griffiths JR
Cancer Chemother Pharmacol; 1998; 42(3):201-9. PubMed ID: 9685055
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of advanced colorectal cancer with long-term continuous infusion of 5-fluorouracil].
Kotake K; Koyama Y; Nasu J; Ando J; Ozawa I; Ogata Y
Gan To Kagaku Ryoho; 1994 Jan; 21(1):47-52. PubMed ID: 8291915
[TBL] [Abstract][Full Text] [Related]
18. Effect of coefficient of viscosity and ambient temperature on the flow rate of drug solutions in infusion pumps.
Kawabata Y
Pharm Dev Technol; 2012; 17(6):755-62. PubMed ID: 21615228
[TBL] [Abstract][Full Text] [Related]
19. [Cardiotoxicity of 5-fluorouracil: a question of formulation].
Lemaire L; Arellano M; Malet-Martino MC; Martino R; De Forni M
Bull Cancer; 1994 Dec; 81(12):1057-9. PubMed ID: 7742593
[TBL] [Abstract][Full Text] [Related]
20. Interest of fluorine-19 nuclear magnetic resonance spectroscopy in the detection, identification and quantification of metabolites of anticancer and antifungal fluoropyrimidine drugs in human biofluids.
Martino R; Gilard V; Desmoulin F; Malet-Martino M
Chemotherapy; 2006; 52(5):215-9. PubMed ID: 16864998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
